Genome Biologics develops therapies for cardiovascular and cardiometabolic diseases, utilizing AI-driven big data analysis for precision preclinical and in vivo disease models.

Genome Biologics

Biotechnology Research

Genome Biologics | 1,261 followers on LinkedIn. Accelerated Drug Development | Genome Biologics identifies viable drug candidates and FDA approved drug repositioning compounds for Cardiovascular and Cardiometabolic disease. Capitalising on the power of our patented Artificial Intelligence (AI) driven preclinical multi-modality drug testing technology - We leverage the power of AI-based machine learning with transformative single cell in vitro and in vivo transgenesis to dramatically reduce the cost, time, and ethical burden of preclinical research in the pharmaceutical industry.

Professor at Goethe-Universität Hospital Frankfurt a. Main

Jaya Krishnan

Head of Research and Drug Discovery at Genome Biologics

Ting Yuan

🚀 Exciting News! 🚀 Genome Biologics is thrilled to announce an exclusive commercialization partnership with InSphero AG! This collaboration grants InSphero global rights to our revolutionary 3D Cardiac Organoid Platform, TrueCardium®. Together, we aim to set a new standard in cardiac disease research and therapeutic development. By combining our cutting-edge organoid technology with InSphero’s expertise, we're paving the way for faster, more accurate 𝐜𝐚𝐫𝐝𝐢𝐨𝐭𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐬𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐩𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐦𝐨𝐝𝐞𝐥𝐬. Stay tuned for more updates as we embark on this groundbreaking journey! 🌟 💡 #Innovation #Biotech #CardiacResearch #Organoids #Partnership #GenomeBiologics #InSphero

📣 BREAKING NEWS 📣 Genome Biologics are honored to be selected for this year's Startup Pitch & Partner Program at #BioVaria ! We look forward to presenting Genome Biologics and connecting with fellow enterpreneurs and broader life science community. At Genome Biologics , we are commited to disrupting and revolutionalising treatments for heart disease and tackling the larger burden of cardiovascular disease in the EU. 👉👉👉 Join us for discussions at #BioVaria and learn about our drug pipeline – with special focus on cardioinflammatory disorder - including clonal hematopoiesis of indeterminate potential (CHIP) #lifescience #cardio #drugpipeline

GENO

COM:GENOMEBIOLOGICS

Genome Biologics

locale

market

industry

website

crunchbase

linkedin

peer of

competitor of

Metrics